Claims

1. Use of lidocaine in the manufacture of a lidocaine tape for treating pain in a patient, the lidocaine tape comprising 1.8 wt% lidocaine such that one or more pharmacokinetic parameters of the tape is within 80 wt. % to 125 wt. % of an aqueous patch containing 5 wt. % lidocaine.

2. The use according to claim 1 wherein the one or more pharmacokinetic parameters of the tape is within 90 wt. % to 125 wt. % of the aqueous patch containing 5 wt. % lidocaine.

3. The use according to claim 1 or 2 wherein the aqueous patch is Lidoderm®.

4. The use according to any one of the preceding claims wherein the pharmacokinetic parameter is the maximum observed plasma concentration (C_{max}).

5. The use according to any one of the preceding claims wherein the pharmacokinetic parameter is the area under the plasma concentration-time curve (AUC_{0-24}).

6. The use according to claim 4 wherein when administered to a patient the C_{max} is from between about 40 to about 160 ng/ml.

7. The use according to any one of the preceding claims wherein the pain is caused by postherpetic neuralgia.

.

8. Use of lidocaine in the manufacture of a lidocaine containing tape comprising 1.8 wt. % lidocaine, 5 to 15 wt. % polyisobutylene, 0.1 to 0.5 wt. % dibutylhydroxytoluene, 10 to 20 wt. % styrene-isoprene-styrene block copolymer, 10 to 30 wt. % terpene resin, 0.1 to 1 wt. % light anhydrous silicic acid, 40 to 55 wt. %

liquid paraffin, 1 to 3 wt. % isostearic acid and 0.1 to 1 wt. % dipropylene glycol for treating pain in a patient, wherein one or more pharmacokinetic parameters of the formulation is within 80 wt. % to 125 wt. % of that of an aqueous patch containing 5 wt. % lidocaine in an aqueous base which also contains dihydroxyaluminum aminoacetate, disodium edetate, gelatin, glycerin, kaolin, methylparaben, polyacrylic acid, polyvinyl alcohol, propylene glycol, propylparaben, sodium carboxymethylcellulose, sodium polyacrylate, D-sorbitol, tartaric acid, and urea and wherein the patch contains 700 mg of lidocaine.

9. The use according to claim 8 wherein the one or more pharmacokinetic parameters of the formulation is within 90 wt. % to 125 wt. % of that of the aqueous patch.

10. The use according to claim 8 or 9 wherein the aqueous patch is Lidoderm®.

11. The use according to any one of claims 8-10 wherein the pharmacokinetic parameter is the maximum observed plasma concentration (C_{max}).

12. The use according to any one of claims 8-11 wherein the pharmacokinetic parameter is the area under the plasma concentration-time curve (AUC_{0-24}).

13. The use according to claim 11 wherein administered to a patient the C_{max} is from between about 40 to about 160 ng/ml.

14. The use according to any one of claims 8-13 wherein when administered to a patient the time-to-maximum observed plasma concentration (T_{max}) is from between about 8 to about 18 hours.

15. The use according to claim 14 wherein when administered to a patient the T_{max} is from between about 10 to about 18 hours.